Clinical impact of stress dose steroids in patients with septic shock: insights from the PROWESS-Shock trial

Table 2 Survival analysis of 28-day and 90-day all-cause mortality (propensity-weighted), all patients, by steroid use at baseline and randomized treatment

Mortality	DrotAA and steroid use^a	DrotAA and no steroid use^a	Hazard ratio^b	Placebo and steroid use^a	Placebo and no steroid use^a	Hazard ratio^b	Interaction P -value^b
Day 28
Estimate	24.8%	29.5%	0.826	23.5%	23.3%	1.001	0.3764
95% CI	20.6, 29.7	25.1, 34.5	0.616, 1.107	19.2, 28.6	19.4, 27.8	0.735, 1.364
Day 90
Estimate	34.1%	37.9%	0.874	32.8%	30.6%	1.074	0.2743
95% CI	29.4, 39.3	33.1, 43.0	0.678, 1.127	27.9, 38.4	26.2, 35.4	0.822, 1.403

^aInverse proportional weighted Kaplan-Meier rate and associated 95% CI. ^bHazard ratios of steroid versus no steroid use and randomized treatment*steroid use interaction P-value obtained using inverse proportional weighted Cox proportional hazards model. Observations weighted by the inverse probability of being prescribed a steroid therapy at baseline using a propensity model including the following variables: age, gender, baseline acute physiology and chronic health evaluation II score, baseline total sequential organ failure assessment, time between first vasopressor and study drug infusion (hours), number of baseline organ dysfunctions (1 to 5), baseline lactate concentration (mmol/L), intravenous (IV) fluids in 24 hours before start of vasopressors (mL), IV fluids from the start of vasopressor to the start of study drug infusion (mL), and baseline vasopressor score. DrotAA, drotrecogin-alfa activated.

ISSN: 1364-8535